The world needs Garp, according to Abbvie
After years of slow progress, and with very little supporting clinical data, Abbvie pledges to push into a major Garp inhibition programme.
Biotech’s key upcoming clinical results
Moderna, Biomarin and Daiichi Sankyo will begin 2023 with important data reveals.
Ash 2022 movers – Glycomimetics shakes off its sickle cell past
Meanwhile, there was bad blood between cell therapy players and their investors.
Ash 2022 – Argenx faces Vyvgart questions
As the group looks to expand into immune thrombocytopenia, there are several reasons to be cautious.
Ash 2022 preview – Argenx’s expansion plans come into focus
Vyvgart gets a prestigious press slot for its next potential use, while Sangamo’s haemophilia A gene therapy mimics Biomarin’s valrox again.
Biotech catalysts on the horizon
The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.
